Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
Benjamin Besse, Elvire Pons‐Tostivint, Keunchil Park, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 716-729
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment
Elizabeth Hardaker, Emilio Sanseviero, Ankur Karmokar, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 13
Beyond Chemoimmunotherapy in Advanced Non–Small Cell Lung Cancer: New Frontiers, New Challenges
Giannis Mountzios, Jarushka Naidoo, Chao Wang, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 13
Immune Checkpoint Inhibitors Rechallenge in Non-Small Cell Lung Cancer: Current Evidence and Future Directions
Xiaoyu Gang, Jinshan Yan, Xin Li, et al.
Cancer Letters (2024) Vol. 604, pp. 217241-217241
Open Access | Times Cited: 12
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
Yvette Drew, Frank T. Zenke, Nicola J. Curtin
Nature Reviews Drug Discovery (2024) Vol. 24, Iss. 1, pp. 19-39
Closed Access | Times Cited: 12
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Jing Wei, Wenke Li, Pengfei Zhang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Relevance of proteomics and metabolomics approaches to overview the tumorigenesis and better management of cancer
Pooja Singh, Yashika Walia, Shagun Gupta, et al.
3 Biotech (2025) Vol. 15, Iss. 3
Closed Access | Times Cited: 1
Versatile Nanomaterials That Interfere with Ferroptosis in the Tumor Microenvironment
Yurong Liu, Yunheng Liu, Xinting Li, et al.
International Journal of Nanomedicine (2025) Vol. Volume 20, pp. 2461-2473
Open Access | Times Cited: 1
Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations
Nikolaj Frost, Martin Reck
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 6
The Coming Age of Antisense Oligos for the Treatment of Hepatic Ischemia/Reperfusion (IRI) and Other Liver Disorders: Role of Oxidative Stress and Potential Antioxidant Effect
Siyuan Yao, Aanchal Kasargod, Richard Chiu, et al.
Antioxidants (2024) Vol. 13, Iss. 6, pp. 678-678
Open Access | Times Cited: 4
Targeting the DNA damage response in cancer
Guffanti Federica, Chiappa Michela, Giovanna Damia
MedComm (2024) Vol. 5, Iss. 11
Open Access | Times Cited: 4
Advances in the Relationship of Immune Checkpoint Inhibitors and DNA Damage Repair
Xiaolin Liu, Shan Wang, Hongwei Lv, et al.
Current Research in Translational Medicine (2025) Vol. 73, Iss. 2, pp. 103494-103494
Closed Access
Resistance to Immunotherapy in Non-small Cell Lung Cancer: Unraveling Causes, Developing Effective Strategies, and Exploring Potential Breakthroughs
Shuang Dong, Xiaoyu Li, Qing Huang, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101215-101215
Closed Access
Eficiência dos inibidores de PD-1 e PD-L1 no tratamento do carcinoma pulmonar de não pequenas células, uma revisão integrativa
Enzo Stella de Carvalho, Lívia Burim Cerreti, Cecília Rioja Gomes, et al.
Caderno Pedagógico (2025) Vol. 22, Iss. 5, pp. e14644-e14644
Closed Access
Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice
Alexandra Fauvre, Chiara Ursino, Véronique Garambois, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e010791-e010791
Open Access
PROGNOSTIC SIGNIFICANCE OF FOXP3 IN RADICALLY TREATED NON-SMALL CELL LUNG CANCER PATIENTS
О. І. Vynnychenko, Yuliia Moskalenko, Artem Piddubnyi, et al.
Art of Medicine (2025), pp. 25-32
Closed Access
STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRASG12C Inhibitors in Nonsmall Cell Lung Cancer
Zehao Pan, Yuxian Qian, Yajing Wang, et al.
Cancer Science (2025)
Open Access
Discovery of the Clinical Candidate YY2201 as a Highly Potent and Selective ATR Inhibitor
Meng Wu, Xiaofang Chen, Haoran Wang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer
Sami Saqf el Hait, Vanita Noronha, Rajiv Chowdhury, et al.
ESMO Open (2025) Vol. 10, Iss. 4, pp. 104479-104479
Closed Access
Perspectives on cancer therapy—synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges
Shixuan Peng, M.D. Long, Qi-Sheng Chen, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Immunotherapy in lung cancer brain metastases
Eunice Paisana, Rita Cascão, Magda Alvoeiro, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
The role of STK11/LKB1 in cancer biology: implications for ovarian tumorigenesis and progression
Jian Kang, Stefania Gallucci, Jian Pan, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 2
Microfluidic Biosensing Platform integrated with flexible sensing array for cancer biomarker point-of-care testing
Yunhong Zhang, Mingyuan Sun, Hongpeng Zhou, et al.
Sensors and Actuators B Chemical (2024), pp. 137148-137148
Closed Access | Times Cited: 2
Immunological profiling for short-term predictive analysis in PD-1/PD-L1 therapy for lung cancer
Yun Wang, Rujia Chen, Zhenzhou Guo, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Role of the TME in immune checkpoint blockade resistance of non-small cell lung cancer
Yuening Dai, Xi Tian, Xuanting Ye, et al.
Cancer Drug Resistance (2024)
Open Access
N6-methyladenosine (m6A) RNA methylation of LncRNA LINC01214 accelerates the progression of non-small cell lung cancer (NSCLC) by targeting miR-195-5p/ROCK1 axis
Xiao-Feng Sun, Chang Liu, Wei Chen, et al.
Cytotechnology (2024) Vol. 77, Iss. 1
Closed Access
Page 1 - Next Page

Scroll to top